Immix Biopharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	62	137	32	26	-	-
Market Cap Growth	-	331.07%	24.43%	-	-	-
Enterprise Value	47	120	18	8	4	3
PE Ratio	-8.91	-8.91	-3.87	-1.05	-	-
PB Ratio	3.93	8.38	2.42	1.43	-	-
P/FCF Ratio	-12.03	-12.03	-4.31	-16.12	-	-
P/OCF Ratio	-12.09	-12.09	-4.31	-16.13	-	-
EV/EBITDA Ratio	-7.79	-7.79	-2.25	-0.33	-3.61	-4.00
EV/EBIT Ratio	-7.79	-7.79	-2.25	-0.33	-3.61	-4.00
EV/FCF Ratio	-10.50	-10.50	-2.49	-5.05	-9.16	-4.22
Debt / Equity Ratio	-	-	-	0.00	-0.87	-1.12
Debt / EBITDA Ratio	-	-	-	0.00	-4.00	-4.87
Debt / FCF Ratio	-	-	-	-0.03	-10.13	-5.14
Quick Ratio	4.70	4.70	10.55	87.33	0.07	0.16
Current Ratio	5.32	5.32	11.70	90.01	0.10	0.20
Interest Coverage	-	-	-16537.12	-134.54	-10.08	-7.66
Return on Equity (ROE)	-100.90%	-100.90%	-48.60%	-367.80%	27.40%	-
Return on Assets (ROA)	-86.70%	-86.70%	-46.10%	-260.30%	-154.90%	-
Return on Capital (ROIC)	-98.39%	-98.39%	-62.45%	-7.49%	71.97%	-185.72%
Earnings Yield	-23.95%	-11.22%	-25.80%	-95.13%	-	-
FCF Yield	-17.74%	-8.31%	-23.23%	-6.20%	-	-
Buyback Yield / Dilution	-24.87%	-24.87%	-278.13%	-8.82%	-	-
Total Shareholder Return	-24.87%	-24.87%	-278.13%	-8.82%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).